Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run?
Teva Pharmaceutical Industries has delivered a very large 259.9% return over the past three years, yet the current valuation picture is more balanced. Recent share price weakness and a mixed overall value score leave investors weighing how much upside is already reflected in the price.
- Over the past three years, Teva Pharmaceutical Industries has returned 259.9%, which puts extra focus on whether the current price leaves enough margin for error.
- The recent $176.5 million jury verdict related to Ajovy can support confidence in Teva's pipeline and cash generation, while the revived Forteo-related lawsuit underlines that litigation outcomes remain a key risk for how the stock is priced.
- Teva scores 4 out of 6 on the broader valuation checks. This points to some areas where the stock looks inexpensive and others where it looks fuller, rather than a clear bargain or clear overvaluation, according to the valuation summary.
The issue now is whether Teva Pharmaceutical Industries' recent pullback offers a reasonable entry point after such a strong multi-year run, or if expectations embedded in the valuation are already demanding.
Does Teva Pharmaceutical Industries Look Undervalued on Earnings?
The P/E ratio suits Teva Pharmaceutical Industries because earnings are a key focus for investors watching its shift toward higher value drugs. Teva currently trades on a P/E of about 22.9x, higher than the Pharmaceuticals industry average of around 14.9x and above the peer group average of roughly 17.9x. This means the stock does not screen cheap against simple sector or peer benchmarks.
However, a more tailored fair P/E of about 26.8x, which factors in Teva’s margins, scale and risk profile, sits above the current multiple. Despite the recent Ajovy verdict and the ongoing Forteo dispute keeping legal risk in view, the valuation model still suggests the market is applying a discount to what might be expected given these fundamentals. The gap between the current 22.9x P/E and the 26.8x fair P/E indicates some potential headroom if earnings remain in line with these expectations.
On the P/E multiple, Teva Pharmaceutical Industries stock currently appears undervalued relative to the fair ratio implied by its fundamentals.
See what the numbers say about this price — find out in our valuation breakdown.
The Teva Pharmaceutical Industries Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Teva Pharmaceutical Industries pick up where the valuation puzzle leaves off and spell out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, as explored on the Community page. Each narrative links its number to a specific view on how Teva Pharmaceutical Industries' growth, profitability and risks could evolve, giving you a reference point to test against new information over time.
One of the top community narratives on Teva Pharmaceutical Industries: 25% undervalued
"Teva's diversified portfolio and expanding branded and biosimilar products are expected to drive steady, higher-margin growth and profitability amid demographic and regulatory tailwinds..."
Read one of the top narratives on Teva Pharmaceutical Industries
Do you think there's more to the story for Teva Pharmaceutical Industries? Head over to our Community to see what others are saying!
The Bottom Line
Teva Pharmaceutical Industries screens as undervalued on its tailored P/E multiple, which points to some room for upside if the current earnings profile holds. However, the broader set of valuation checks is mixed rather than overwhelmingly supportive, so the pricing is not a clear giveaway. From here, the key question is whether Teva’s earnings power can steadily support that higher implied multiple while legal and regulatory risks, such as ongoing litigation, remain contained enough that the current discount does not prove to be a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com